Contrasting ProKidney (NASDAQ:PROK) & Evaxion Biotech A/S (NASDAQ:EVAX)

ProKidney (NASDAQ:PROK) and Evaxion Biotech A/S (NASDAQ:EVAX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, analyst recommendations, risk, institutional ownership, profitability and earnings.

Profitability

This table compares ProKidney and Evaxion Biotech A/S’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ProKidney	N/A	N/A	-8.80%
Evaxion Biotech A/S	N/A	N/A	-108.14%

Institutional and Insider Ownership

51.6% of ProKidney shares are held by institutional investors. Comparatively, 11.0% of Evaxion Biotech A/S shares are held by institutional investors. 41.5% of ProKidney shares are held by insiders. Comparatively, 41.6% of Evaxion Biotech A/S shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Earnings & Valuation

This table compares ProKidney and Evaxion Biotech A/S”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ProKidney	N/A	N/A	-$35.47 million	($0.57)	-2.95
Evaxion Biotech A/S	$278,000.00	58.39	-$22.12 million	($2.35)	-1.24

Evaxion Biotech A/S has higher revenue and earnings than ProKidney. ProKidney is trading at a lower price-to-earnings ratio than Evaxion Biotech A/S, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

ProKidney has a beta of 1.08, meaning that its stock price is 8% more volatile than the S&P 500. Comparatively, Evaxion Biotech A/S has a beta of -0.26, meaning that its stock price is 126% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings for ProKidney and Evaxion Biotech A/S, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ProKidney	0	3	2	0	2.40
Evaxion Biotech A/S	0	0	2	0	3.00

ProKidney currently has a consensus target price of $4.50, indicating a potential upside of 167.86%. Evaxion Biotech A/S has a consensus target price of $11.00, indicating a potential upside of 278.01%. Given Evaxion Biotech A/S’s stronger consensus rating and higher possible upside, analysts clearly believe Evaxion Biotech A/S is more favorable than ProKidney.

Summary

Evaxion Biotech A/S beats ProKidney on 6 of the 10 factors compared between the two stocks.

About ProKidney

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.

About Evaxion Biotech A/S

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers. Its programs also include some vaccines that are in pre-clinical stage, which includes EVX-B1 for the prevention of S. aureus-induced skin and soft tissue infections in patients undergoing elective abdominal hernia surgery; EVX-B2 to target diseases caused by N. gonorrhoeae; EVX-B3 for eliciting strong humoral antibody and cellular immune response to the bacterial pathogen; and EVX-V1, viral vaccine product candidate for targeting Cytomegalovirus. Evaxion Biotech A/S was incorporated in 2008 and is based in Horsholm, Denmark.